The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice.

Neuropharmacology
Dean T AchesonVictoria B Risbrough

Abstract

Pregabalin, an anticonvulsant and anxiolytic compound that binds to α2-δ auxiliary subunit Types 1 and 2 of voltage-gated calcium channels, has been shown to reduce excitatory neurotransmission partially through modulation of glutamatergic signaling. Prepulse inhibition (PPI) of startle is an operational measure of sensorimotor gating impacted by disruption of the glutamatergic system and is reduced in schizophrenia patients. Dysregulation of the glutamatergic system has also been implicated in the pathophysiology of schizophrenia. Here we tested the hypothesis that pregabalin may ameliorate PPI in a model of deficient gating in humans and mice. In study 1, 14 healthy human subjects participated in a within subjects, cross-over study with placebo, 50 mg or 200 mg pregabalin treatment prior to undergoing a PPI task. In study 2, 24 C57BL/6 mice underwent a similar procedure with vehicle, 30 and 100 mg/kg dose treatments. In both studies, subjects were assigned to a "Low" or "High" gating group using a median split procedure based on their PPI performance during placebo/vehicle. Drug effects were then examined across these groups. In humans, pregabalin treatment significantly increased PPI performance in the "low gating" group. In...Continue Reading

References

Mar 1, 1992·Archives of General Psychiatry·D L BraffM A Geyer
Feb 25, 1998·Behavioural Brain Research·M Koch, H U Schnitzler
Jan 14, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·K M CecilR C Gur
Mar 14, 2002·Depression and Anxiety·S LudewigF X Vollenweider
Apr 12, 2003·Neuropharmacology·Kathryn M AbelMark A Geyer
Jun 18, 2003·Seizure : the Journal of the British Epilepsy Association·Laura D Errante, Ognen A C Petroff
Apr 23, 2004·Psychophysiology·Tanja JovanovicErica J Duncan
Dec 21, 2004·Biological Psychiatry·Victoria B Risbrough, Mark A Geyer
Feb 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowJody M Shoemaker
Jun 13, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Richard Kavoussi
Feb 7, 2007·British Journal of Pharmacology·A Gogos, M van den Buuse
Mar 8, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ebony R SamuelsChristopher M Bradshaw
Apr 27, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Philipp A CsomorFranz X Vollenweider
Dec 13, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·B BrawekT J Feuerstein
Jun 10, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stella G GiakoumakiPanos Bitsios
Dec 17, 2008·Trends in Pharmacological Sciences·Mark A Geyer, Franz X Vollenweider
Jan 17, 2009·Psychopharmacology·Jo A TalledoNeal R Swerdlow
Feb 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·N R SwerdlowJ Talledo
Jun 10, 2010·Journal of Clinical Psychopharmacology·Susanne EnglischMathias Zink
Jan 21, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen M AlseneVaishali P Bakshi
Feb 19, 2011·The International Journal of Neuropsychopharmacology·Maarten van den BuuseVictoria Risbrough
Mar 2, 2011·Current Pharmaceutical Design·Shigeyuki Chaki, Hirohiko Hikichi
Jun 10, 2011·European Journal of Pharmacology·Zheng LiSean Donevan
Sep 6, 2011·Journal of Psychopharmacology·Dominique H HolsteinFranz X Vollenweider
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bita Moghaddam, Daniel Javitt
Jan 6, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Susanne E AhmariH Blair Simpson

❮ Previous
Next ❯

Citations

Apr 2, 2013·International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology·Mirjam J van TrichtDorien H Nieman
Aug 8, 2015·Journal of Affective Disorders·Dean T AchesonVictoria B Risbrough
Apr 29, 2015·Expert Review of Clinical Pharmacology·Mathias Zink, Christoph U Correll
Jul 1, 2020·Psychopharmacology·Fatma Duygu Kaya-YertutanolHayrunnisa Bolay-Belen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.